# Developmental Funds

> **NIH NIH P30** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2022 · $828,396

## Abstract

CCSG COMPONENT 002 – DEVELOPMENTAL FUNDS
PROJECT SUMMARY/ABSTRACT
Developmental Funds are critical to the success of the Vanderbilt-Ingram Cancer Center (VICC) and provide
essential support to further VICC Strategic Directions. During the current project period, this support was applied
toward the recruitment of new faculty, pilot projects, development of shared resources and support for staff
investigators. Eight new faculty members were provided with recruitment support, including five key leadership
recruitments in the areas of: cancer disparities; translational research and precision oncology; gastrointestinal
cancer; medical oncology, training and research integration; and radiation oncology. A total of 14 pilot projects
were funded over the project period with significant publications and return on investment of ~ 10-fold in terms
of subsequent funding from extramural sources. Additionally, funds were used to support seven staff
investigators and the evolution of the Immunophenotyping Shared Resource from the Antibody Production
Shared Resource. A request of $220,000 per year is made to support new faculty recruitments in targeted
strategic areas, including but not limited to cancer genetics; genomics and epigenetics; immunology and
immunophenotyping; precision oncology; genitourinary and hematologic malignancies; phase I drug
development and pharmacology; cancer epidemiology and population-based research; screening and early
detection; and cancer control. A request of $150,000 per year will support three types of pilot projects: 1) highly
innovative projects focusing on proof-of-concept or translational research, 2) preliminary collaborative
investigations leading to multi-investigator grants, and 3) projects that closely align to the VICC Strategic
Directions. Developmental funds will also be used to support seven Staff Investigators across the categories of
Research, Clinical, and Special Populations. Additionally, $65,000 per year is requested to support early-stage
clinical investigators who are actively involved in VICC clinical research efforts through trial leadership, trial
development, and recruitment of patients to clinical trials. VICC has a proven track record in stewardship of these
funds as measured by the return-on-investment in people and projects that advance discoveries to patients and
community. The total budget requested, in concert with the continued commitment of VICC discretionary funds,
enables the Director to support activities critical to the sustained research excellence of VICC.

## Key facts

- **NIH application ID:** 10488778
- **Project number:** 5P30CA068485-27
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** Ben Ho Park
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $828,396
- **Award type:** 5
- **Project period:** 1998-09-01 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10488778

## Citation

> US National Institutes of Health, RePORTER application 10488778, Developmental Funds (5P30CA068485-27). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10488778. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*